These findings suggest that SGLT2 inhibitor prevention of cognitive decline in those models is related to the reduction in cerebral oxidative stress, alleviation of cerebral atherosclerosis and suppression of microglia‐mediated neuroinflammation. Here, SLC5A2 is linked to cerebral atherosclerosis.